Emerging approaches for the treatment of Alzheimer disease: Targeting
NF-κB pathway
Abstract
Alzheimer’s disease (AD) is the most predominant neurodegenerative
disorder and form of dementia around the globe. Despite its prevalence,
only a few drugs approved for AD and all concerned with the symptoms
rather than the underlying cause of the disorder. Classic
neuropathological disease hallmarks (β-amyloid & NFT) and sporadic AD
risk genes APOE that activate NF-κB, yet may incite pathology. NF-κB
inhibition is a current strategy to counter neuroinflammation and
neurodegeneration in the brain of individuals with AD, and numbers of
NF-κB modulators are being examined in clinical trials. Modification of
the NF-κB system focuses mainly on preventing oxidative stress with the
pathway to cell death and managing the levels of neurotransmitters. This
review summarizes several shreds of evidence indicating the upregulation
of NF-κB in AD and illustrates its function in current efforts for a
therapeutic approach. The goal of innovative research strategies is to
modulate NF-κB, providing an alternate treatment that may help
individuals with AD and generate hope for potential clinical
advancements in AD.